Mehd7945a

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Mehd7945a is an investigational drug, meaning it is still being studied in clinical trials and is not yet approved for treating colorectal cancer. It is being investigated as a potential treatment option for people with metastatic colorectal cancer (mCRC) whose cancer has progressed after initial treatment with oxaliplatin-based chemotherapy. Specifically, studies are focusing on patients whose tumors have wild-type KRAS genes. In a Phase 2 clinical trial, Mehd7945a was combined with FOLFIRI chemotherapy (folinic acid, 5-fluorouracil, and irinotecan) and compared to cetuximab combined with FOLFIRI in patients with KRAS wild-type mCRC. The goal of this trial was to assess the safety and effectiveness of adding Mehd7945a to standard chemotherapy.

Mechanism of Action

The specific way Mehd7945a works (its molecular target or mechanism of action) is not fully detailed in the available trial information. It is being studied in combination with FOLFIRI chemotherapy. The trial aims to see if adding Mehd7945a to this chemotherapy regimen improves outcomes compared to adding cetuximab to the same regimen in patients with KRAS wild-type metastatic colorectal cancer.

Side Effects

As Mehd7945a is an investigational drug Its side effect profile is still being evaluated in ongoing clinical trials. The trial mentioned (NCT01652482) is designed to assess the safety of Mehd7945a when combined with FOLFIRI chemotherapy. Common side effects associated with FOLFIRI chemotherapy include nausea Vomiting Diarrhea Fatigue And low blood counts. Cetuximab The drug used in the comparison arm Can cause skin reactions Diarrhea And infusion-related reactions. The specific side effects related to Mehd7945a itself will become clearer as more data from clinical trials become available.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01652482 Phase 2
Archived
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
United States, Australia, Belgium, France, Germany, Italy, New Zealand, Romania,

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.